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TB remains the leading infectious killer worldwide, with 1.4 million deaths in 2019;1 10 million new 
cases occur annually, disproportionately affecting dis-
advantaged populations, thus rightly maintaining its 
place in the Sustainable Development Goals (SDG), 
whose guiding principle is “to leave no one behind”. 
The WHO End TB Strategy has expanded the SDGs to 
reduce TB deaths by 95% and new cases by 90% be-
tween 2015 and 2035.2
However, at the end of 2019, the world as a whole 
and many high TB burden countries were not on track 
to reach the 2020 milestones of the End TB Strategy.1 
While globally TB incidence rates have been falling, 
the decrease is unacceptably slow. The cumulative re-
duction from 2015 to 2019 was only 9%, which is far 
below the 20% reduction aimed for between 2015 and 
2020. In addition, the SARS-CoV-2 pandemic is ex-
pected to undo some of the TB control achievements 
obtained in the last decade.3,4
Zimbabwe is among the 14 countries with a triple 
burden of TB, TB-HIV and multidrug-resistant TB 
(MDR-TB). In 2018, the estimated incidence of TB in 
Zimbabwe was 210 per 100,000 population, and 62% 
of diagnosed TB patients were HIV co-infected; HIV 
prevalence was even higher (80%) among MDR-TB pa-
tients.1,5 Zimbabwe was not spared from the SARS-
CoV-2 pandemic, and like most countries in the 
sub-Saharan African region, implemented a national 
lockdown in March 2020,6 resulting in considerable 
reduction in TB notifications in most provinces.
In Zimbabwe, the roll-out of the Xpert® MTB/RIF 
assay (Cepheid, Sunnyvale, CA, USA) started in 2012 
following the WHO policy recommendations on using 
Xpert testing in 2011.7 Initially Xpert testing was re-
served for those with HIV infection, diabetes, history 
of previous TB treatment, presumed extrapulmonary 
TB, MDR-TB contacts, healthcare workers, miners, 
pregnant women, children aged 5 years and the el-
derly aged 60 years (‘restricted algorithm’). Also, pa-
tients on first-line treatment with smear-positive spu-
tum samples at 2 months were offered investigations 
using Xpert. In 2017, the Zimbabwe Tuberculosis and 
Leprosy Management Guidelines recommended a new 
diagnostic TB algorithm (‘unrestricted’),8 where Xpert 
was recommended as the primary diagnostic for all 
patients presenting with symptoms suggestive of TB. 
Implementation of the new diagnostic algorithm was 
influenced by Xpert testing capacity, including the 
number of GeneXpert testing sites, number of instru-
ments and modules per instrument, procurement of 
cartridges and sample transport systems.
The aim of this study was to present provin-
cial-level data from Manicaland in Zimbabwe for 2017 
to 2018 which spans the transition from implementa-
tion of the ‘restricted’ to the ‘unrestricted’ diagnostic 
algorithm.
METHODS
The retrospective study was conducted in Manicaland, 
one of the 10 provinces in Zimbabwe between 1 Janu-
ary 2017 and 31 December 2018.
Study setting
According to the last census, Manicaland had a popu-
lation of 1.75 million in 2012.9 This population is 
served by 304 health facilities: 7 district hospitals, 66 
mission hospitals, 9 rural hospitals and 222 primary 
health clinics. All facilities despite level of operation, 
provide TB investigations and treatment. The facility 
ownership comprises government, mission, rural dis-
trict council, municipality and commercial entities. 
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SETTING: Governmental health facilities performing TB 
diagnostics in Manicaland, Zimbabwe.
OBJECTIVE: To investigate the effect of making Xpert® 
MTB/RIF the primary TB diagnostic for all patients pre-
senting with presumptive TB on 1) the number of sam-
ples investigated for TB, 2) the proportion testing TB-pos-
itive, and 3) the proportion of unsuccessful results over 
time.
DESIGN: This retrospective study used data from GeneX-
pert downloads, laboratory registers and quality assurance 
reports between 1 January 2017 and 31 December 2018.
RESULTS: The total number of Xpert tests performed in 
Manicaland increased from 3,967 in the first quarter of 
2017 to 7,011 in the last quarter of 2018. Mycobacterium 
tuberculosis DNA was detected in 4.9–8.6% of the sam-
ples investigated using Xpert, with a higher yield in 2017 
than in 2018. The overall proportion of unsuccessful 
Xpert assays due to “no results”, errors and invalid results 
was 6.3%, and highly variable across sites.
CONCLUSION: Roll out of more sensitive TB diagnostics 
does not necessarily result in an increase of microbiologi-
cally confirmed TB diagnosis. While the number of sam-
ples tested using Xpert increased, the proportion of 
TB-positive tests decreased. GeneXpert soft- and hard-
ware infrastructure needs to be strengthened to reduce 
the rate of unsuccessful assays and therefore, costs and 
staff time.
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The health facilities are served by 15 GeneXpert testing sites lo-
cated across all seven districts. All GeneXpert testing sites also of-
fer smear microscopy. Smear microscopy is also performed at 15 
additional microscopy centres. The first GeneXpert 4-modular 
machine was introduced in Manicaland in 2010 and since then a 
total of 16 4-modular machines have been placed across the 
province.
Data collection
Data on all samples submitted to the 15 GeneXpert sites were 
downloaded directly from the GeneXpert machines and anony-
mised. Additional data for each of the processed samples were ex-
tracted from the TB laboratory registers. The extracted data included 
referring health facility, date of sample collection, date of sample re-
ceipt in the laboratory, age, sex and HIV status of the person.
Direct data downloads for some GeneXpert testing sites were 
not available for certain time periods due to hardware problems, 
software failures and limited back-up. Data were extracted from 
provincial TB external quality assurance reports to allow assess-
ment of the change in 1) the number of tests performed using 
Xpert and microscopy, 2) the number of microbiologically TB di-
agnoses made, 3) the number of rifampicin-resistant TB diagno-
ses, and 4) the proportion of samples with error, and invalid and 
no results over time. Errors are due to instrument, cartridge or 
handling errors. Examples include the instrument failing to reach 
a certain temperature, cartridges not being airtight or bubbles in-
troduced during sample preparation. Results are categorised as in-
valid if the internal control failed, indicating polymerase chain 
reaction inhibition due to blood, food rests or pus. Tests that are 
terminated due to interrupted power supply, software failure or 
manual abortion of a run are categorised as “no result”.
Analyses were performed using Stata v16.0 (Stata, College Sta-
tion, TX, USA) and R v4.0.3 (R Foundation for Statistical Comput-
ing, Vienna, Austria). Data were coded as consecutive quarterly 
time periods, for example January 2017 to end of March 2017 was 
coded quarter (Q) 1 and October 2018 to end of December 2018 
coded as Q8. The change in patient characteristics, the proportion 
of samples testing positive for TB and the proportion of samples 
with rifampicin resistance as well as delays due to sample trans-
port were analysed by quarter. The assumption was that data lost 
due to hard and software failures were missing completely at ran-
dom and hence proportions, medians and interquartile ranges 
were calculated using a complete case analysis approach. The data 
extracted from external quality assurance were presented as total 
counts stratified by quarter to investigate trends.
Ethical approval was sought from Manicaland Provincial Medi-
cal Directorate of Ministry of Health and Child Care, Mutare, 
Zimbabwe. Both the Africa University Research Ethics Committee 
(Mutare, Zimbabwe) and Medical Research Council of Zimbabwe 
(Harare, Zimbabwe) approved the study.
RESULTS
The total number of samples tested with Xpert in 2017–2018 was 
43,809, of which respectively 7,865 (18.0%) and 35,944 (82.0%) 
were tested using the restricted and unrestricted algorithms. The 
restricted algorithm was phased out during 2017; by Q5 (January–
March 2018), the whole province had adopted the unrestricted 
algorithm. The total number of Xpert tests increased steadily up 
to Q6 (April–June 2018) (Figure 1), with 3,967 tests performed in 
the Q1 of 2017 and 7,011 in the last quarter of 2018. In total, 
15,719 samples were investigated using smear microscopy over 
the 2 years. However, smear microscopy made up almost half 
(51.0%) of the investigations in Q1 and Q2 (January–June 2017), 
but decreased to 4.2% and 279 in Q8 (October–December 2018), 
as Xpert testing increased. To note, diagnostic algorithms recom-
mend at least two sputum samples per patient to be investigated 
when using smear microscopy, only one sputum sample per pa-
tients is tested when using Xpert.
In 2017 and 2018, 266 of the 304 health facilities in Mani-
caland submitted samples for GeneXpert analysis (Figure 2). The 
median number of referred samples per peripheral health facility 
for Xpert testing in Q5 when all health facilities had adopted the 
unrestricted algorithm was 34 (interquartile range [IQR] 10–85). 
Despite the number of Xpert tests increasing over time, the num-
ber of microbiologically confirmed TB diagnosis did not change 
significantly over the 2 years (Figure 1). The proportion of posi-
tive tests for TB among samples tested using Xpert ranged from 
4.9% to 8.6%.
FIGURE 1 Number of samples tested for TB by quarter and diagnostic tests. Light 
grey = negative tests; dark grey = positive tests.
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There were fluctuations in the number of rifampicin-resistant 
diagnoses, ranging from 13 to 43, with the highest number diag-
nosed in Q3 and Q8. The proportion of samples with “no result” 
varied greatly across GeneXpert sites, with a median of 1.5% (IQR 
1.0–2.2) (Figure 3). The median proportion of samples with an in-
valid or error result was respectively 1.4% (IQR 1.1–1.7) and 3.4% 
(IQR 2.5–4.5) per site.
More detailed data were available for 36,055 samples (82.3%) 
(Table). The proportion of available data (compared to data from 
the external quality assurance audit) ranged between 56.5% to 
93.9%. Reasons for missing data were mainly hardware or soft-
ware failures and the unavailability of external hard-drives for 
back-up. Roll out of the unrestricted algorithm from 5% in Q1 to 
100% in Q5 did not affect the proportion of samples sent from 
peripheral and central sites. In addition, age and sex distributions 
did not change over time (Table). However, the proportion of 
samples submitted from HIV-negative individuals increased from 
40.3% in Q1 to 54.2% in Q5. Bacterial burden as categorised by 
the instrument (high, medium, low, very low) varied over time 
without a clear pattern. The median number of days between 
sample submission and receipt at the GeneXpert sites increased 
slightly: 1 day in Q1, Q3, Q4 and Q5, and 2 days in Q2, Q6, Q7 
and Q8.
DISCUSSION
The implementation of a new diagnostic algorithm that extended 
Xpert testing to all patients with presumptive TB resulted in a 
doubling of the number of Xpert tests. At the same time, the 
number of smear microscopies decreased significantly. The pro-
portion of TB-positive Xpert tests decreased from 8.5% at the start 
of 2017 to 6.5% at the end of 2018. Despite the doubling in the 
number of Xpert tests and the increased sensitivity of Xpert com-
pared to smear microscopy,10 the change in algorithm did not in-
crease the number of microbiologically confirmed TB diagnoses.
A previous study from Manicaland comparing data from Janu-
ary to June 2016 with the same period in 2017 reported similar 
results. The proportion of samples testing TB-positive halved from 
13% in 2016 to 7% in 2017. Over the same time period, the num-
ber of TB notifications increased slightly from 967 to 1,011, and 
the proportion microbiologically confirmed from 48% to 53%.11
Differences in patient population and their pre-test probabil-
ity, for example, the testing of a higher proportion of HIV-nega-
tive individuals may explain the decrease in the proportion of 
TB-positive Xpert tests over time. Changes in the patient popula-
tion tested were a direct result of the new algorithm. Furthermore, 
secular trends may explain the decreasing yield observed in the 
study. Also, more accessible molecular diagnostics may reduce the 
threshold for TB testing resulting in patients with lower TB risk to 
be offered testing. While lowering the threshold for TB testing 
may not necessarily result in increased TB diagnosis, it may lead 
to earlier diagnosis and reduce the period of infectiousness, as 
well as the identification of those who are “hard to diagnose”.12 
Patients and their families may benefit from an earlier diagnosis 
in several ways: 1) decreased morbidity resulting in increased 
quality of life at the end of treatment; 2) reduced cost during the 
diagnostic period; and 3) reduced onward transmission and sec-
ondary cases. However, a TB yield of only 5.4% among samples 
referred for Xpert testing seems particularly low compared to 
studies conducted both in Zimbabwe and elsewhere.13,14 More de-
tailed investigations are therefore needed to understand the tem-
poral association between Xpert roll-out and the decreasing pro-
portion of samples with positive Xpert results.
Despite a doubling in the number of samples being referred for 
Xpert testing, transport time changed minimally over time. The 
median transport time (1 day, IQR 1–3) did not vary between pe-
FIGURE 2 Laboratory network in Manicaland. GeneXpert sites are 
coloured squares; referring facilities are the coloured circles. Usually 
referring facilities refer samples to the nearest GeneXpert site with 
few exceptions due to administrative reasons.
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Restricted 95.0 46.1 22.7 10.2 0 0 0 0
Unrestricted 5.0 53.9 77.3 89.8 100.0 100.0 100.0 100.0
Referral centre
Peripheral 48.0 50.5 49.4 43.7 45.9 55.2 50.1 54.7
Central 52.0 49.5 50.6 57.0 54.1 44.8 49.9 45.3
HIV
Negative 40.3 41.3 46.9 50.2 54.2 55.3 56.6 54.1
Positive 48.8 45.4 38.3 35.2 32.4 31.12 30.3 33.2
Unknown 10.9 13.3 14.8 14.6 13.4 13.54 13.1 12.7
Age, years
5 1.7 1.4 2.0 1.3 1.4 1.4 1.4 2.1
5–14.9 8.7 9.9 8.1 10.4 7.3 9.4 9.3 9.9
15–59.9 67.6 68.5 68.0 67.7 68.9 67.5 65.7 66.2
>60 22.0 20.2 21.9 20.6 22.4 21.7 23.6 21.8
Sex
Male 45.4 43.9 44.4 46.8 41.4 43.4 44.8 42.0
Female 53.1 54.8 54.8 52.1 57.4 55.6 54.0 56.1
Missing 1.5 1.3 0.8 1.1 1.2 1.0 1.2 1.9
TB prevalence 8.3 7.4 6.4 7.3 6.0 5.7 4.8 5.3
RR-TB prevalence 2.7 3.9 10.5 5.5 3.6 2.5 3.8 9.1
TB bacterial burden
High 28.2 16.9 26.0 19.0 20.8 23.6 14.8 17.8
Medium 31.3 41.1 27.9 32.6 30.5 28.8 32.4 37.0
Low 23.2 27.0 27.5 32.1 23.0 26.7 25.2 27.9
Very low 17.3 15.0 18.6 16.3 25.7 20.9 27.6 17.3
Transport time to laboratory, days, median (IQR) 1 (1–3) 2 (1–3) 1 (1–3) 1 (1–3) 1 (1–2) 2 (1–2) 2 (1–3) 2 (1–2)
Q = quarter; RR-TB = rifampicin-resistant TB; IQR = interquartile range.
FIGURE 3 Proportion of samples with an invalid, error or no result by GeneXpert 
site. PH = provincial hospital site; D1, D6 = district hospital site; R1, R6 = sites at rural 
hospitals and health centres; Oth1, Oth2 = other sites (non-governmental organisa-
tion; urban council hospital).
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ripheral and central sites, evidence of a well-organised sample 
transport system in Manicaland. The overall proportion of unsuc-
cessful Xpert assays due to “no results”, errors and invalid results 
was 6.3%, and highly variable across sites. Unsuccessful assays are 
tracked as part of the Xpert key performance indicators (KPI) by 
the Zimbabwe National TB Programme. For the purpose of quality 
management, KPI targets are set at 3% error, 1% invalid, 1% 
no result rates, which only 2 of the 15 GeneXpert sites achieved. 
Other studies investigating the operational challenges of Xpert 
roll-out reported similar unsuccessful assay rates, at 6.0–
10.6%.11,13,14 Unfortunately, none of these studies further anal-
ysed the unsuccessful assay results. A significant proportion of 
unsuccessful assays in this study were categorised as “no result”, 
which usually occur as a result of power cuts, leading to inter-
rupted analytical runs. Specifically, the GeneXpert site with the 
highest “no result” rate (7%) had no electric back up (generator or 
solar) for potential power supply disruptions which are frequent 
in Zimbabwe.
This study has several strengths. First, the study included more 
than 40,000 records from routine services over a 2-year period by 
extracting aggregated data from audit reports and individual-level 
data from GeneXpert downloads supplemented by data from lab-
oratory registers. This allowed investigations beyond the number 
of samples and the number of TB-positive samples over time. Sec-
ond, the study also investigated operational data, including trans-
port time and rates of unsuccessful assays, which are important 
when substantial changes are made within diagnostic networks. 
However, the study also has limitations. These include a high pro-
portion of missing data due to hard- and software failures and in-
dividual-level data being limited to a small set of variables re-
ported in the laboratory register. Aggregated data from audit 
reports could not be de-duplicated; however, this is more import-
ant for smear microscopy samples as most patients investigated 
would have been asked to submit two samples. Also, because data 
were extracted from laboratory registers, patient-relevant out-
comes such as symptoms, and duration of symptoms at diagnosis, 
as well as post-treatment morbidity were not available. Therefore, 
the effect of Xpert roll-out on patient-relevant outcomes could 
not be assessed.
This study demonstrates that a broader roll-out of more sen-
sitive TB diagnostics does not necessarily result in increased 
number of microbiologically confirmed TB diagnosis. Further 
investigations into the reasons for a decreasing prevalence of 
TB among the samples tested are needed. Direct downloads 
from GeneXpert machines are feasible; however, to make the 
best use of these downloads for surveillance, soft- and hard-
ware infrastructure needs to be strengthened. Ensuring contin-
uous electricity supply is equally important to reduce the rate 
of unsuccessful assays, and hence, costs and staff time. Further-
more, there is a need for additional research to evaluate the im-
pact of the change in testing strategies on patient-relevant 
outcomes.
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LIEU : Centres de soins gouvernementaux réalisant des tests 
diagnostiques de la TB au Manicaland, Zimbabwe.
OBJECTIF : Analyser l’effet de l’utilisation du test Xpert® MTB/RIF en 
tant que test diagnostique principal de la TB chez tous les patients 
suspects de TB sur 1) le nombre d’échantillons analysés pour TB, 2) la 
proportion d’échantillons testés positifs à la TB et 3) la proportion de 
résultats infructueux au fil du temps.
MÉTHODE : Cette étude rétrospective a utilisé les données extraites 
du système GeneXpert, des registres de laboratoire et des rapports 
d’assurance qualité entre le 1er janvier 2017 et le 31 décembre 2018.
RÉSULTATS : Le nombre total de tests Xpert réalisés au Manicaland 
a augmenté, de 3 967 au premier trimestre 2017 à 7 011 au dernier 
trimestre 2018. L’ADN de Mycobacterium tuberculosis a été détecté 
dans 4,9–8,6% des échantillons analysés par test Xpert, avec un 
rendement plus élevé en 2017 qu’en 2018. La proportion globale de 
tests Xpert infructueux en raison d’une « absence de résultat », 
d’erreurs ou de résultats non valides était de 6,3%, avec une forte 
variation en fonction des sites.
CONCLUSION : Le déploiement de tests diagnostiques de la TB 
plus sensibles n’entraîne pas nécessairement une hausse des 
diagnostics de TB confirmés microbiologiquement. Alors que le 
nombre d’échantillons testés par test Xpert a augmenté, la proportion 
de tests positifs pour la TB a diminué. L’infrastructure du matériel et 
du logiciel GeneXpert doit être renforcée pour réduire le taux de tests 
infructueux, et donc les coûts et le temps consacré par le personnel à 
la réalisation de ces tests.
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